Online citations, reference lists, and bibliographies.
← Back to Search

A Prospective Study Of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, And Prostate Cancer

H. Li, M. Stampfer, J. Hollis, L. Mucci, J. Gaziano, D. Hunter, E. Giovannucci, J. Ma
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Vitamin D insufficiency is a common public health problem nationwide. Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk. Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms. METHODS AND FINDINGS During 18 y of follow-up of 14,916 men initially free of diagnosed cancer, we identified 1,066 men with incident prostate cancer (including 496 with aggressive disease, defined as stage C or D, Gleason 7-10, metastatic, and fatal prostate cancer) and 1,618 cancer-free, age- and smoking-matched control participants in the Physicians' Health Study. We examined the associations of prediagnostic plasma levels of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, and explored whether relations between vitamin D metabolites and prostate cancer were modified by the functional VDR FokI polymorphism, using conditional logistic regression. Among these US physicians, the median plasma 25(OH)D levels were 25 ng/ml in the blood samples collected during the winter or spring and 32 ng/ml in samples collected during the summer or fall. Nearly 13% (summer/fall) to 36% (winter/spring) of the control participants were deficient in 25(OH)D (<20 ng/ml) and 51% (summer/fall) and 77% (winter/spring) had insufficient plasma 25(OH)D levels (<32 ng/ml). Plasma levels of 1,25(OH)2D did not vary by season. Men whose levels for both 25(OH)D and 1,25(OH)2D were below (versus above) the median had a significantly increased risk of aggressive prostate cancer (odds ratio [OR] = 2.1, 95% confidence interval [CI] 1.2-3.4), although the interaction between the two vitamin D metabolites was not statistically significant (pinteraction = 0.23). We observed a significant interaction between circulating 25(OH)D levels and the VDR FokI genotype (pinteraction < 0.05). Compared with those with plasma 25(OH)D levels above the median and with the FokI FF or Ff genotype, men who had low 25(OH)D levels and the less functional FokI ff genotype had increased risks of total (OR = 1.9, 95% CI 1.1-3.3) and aggressive prostate cancer (OR = 2.5, 95% CI 1.1-5.8). Among men with plasma 25(OH)D levels above the median, the ff genotype was no longer associated with risk. Conversely, among men with the ff genotype, high plasma 25(OH)D level (above versus below the median) was related to significant 60% approximately 70% lower risks of total and aggressive prostate cancer. CONCLUSIONS Our data suggest that a large proportion of the US men had suboptimal vitamin D status (especially during the winter/spring season), and both 25(OH)D and 1,25(OH)2D may play an important role in preventing prostate cancer progression. Moreover, vitamin D status, measured by 25(OH)D in plasma, interacts with the VDR FokI polymorphism and modifies prostate cancer risk. Men with the less functional FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this cancer in the presence of low 25(OH)D status.
This paper references
Inhibition of prostate cancer metastasis in vivo: A comparison of PLoS Medicine | www.plosmedicine.org March 2007 | Volume 4 | Issue 3 | e103 1,23-dihydroxyvitamin D (calcitriol) and EB1089
Bl Lokeshwar (1999)
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
P. Gann (1996)
10.1016/S0960-0760(98)00054-5
Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate
M. Kivineva (1998)
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition.
J. Y. Hsu (2001)
10.1056/nejm198907203210301
Final report on the aspirin component of the ongoing Physicians' Health Study.
(1989)
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
G. Schwartz (1990)
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression.
Y. Xu (2003)
10.1158/0008-5472.CAN-04-3134
Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer.
E. John (2005)
10.1007/BF00051795
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
M. Braun (2004)
Steering Committee of the Physicians' Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians' Health Study
10.1359/jbmr.1997.12.6.915
A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women
H. Arai (1997)
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
E. Corder (1993)
10.1210/ENDO.132.5.7682937
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
R. Skowroński (1993)
10.1016/S0022-5347(05)00958-4
A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk.
S. Berndt (2006)
The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
G. Miller (1992)
10.1023/A:1008835903714
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis
E. Giovannucci (2004)
Serum vitamin D metabolite levels and the subsequent development of prostate cancer
AM Nomura (1998)
10.1093/JN/135.2.332
Vitamin D insufficiency in North America.
D. Hanley (2005)
10.1093/JN/135.2.317
Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D.
B. Hollis (2005)
10.1002/ijc.11375
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries
P. Tuohimaa (2004)
Benefits and requirements of vitamin D for optimal health: a review.
W. Grant (2005)
10.1023/B:CACO.0000024245.24880.8a
Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer
E. Platz (2004)
10.1093/CLINCHEM/39.3.529
Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer.
B. Hollis (1993)
Avioli LV (1987) Diagnosis, staging, and surgical treatment of prostatic carcinoma
WJ Catalona (1987)
10.1023/A:1008923802001
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies.
S. Ingles (1997)
10.1002/jcb.10342
Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer
T. Chen (2003)
Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate.
M. S. Lucia (1995)
10.1016/j.jsbmb.2004.03.063
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
E. Jacobs (2004)
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
J. Ma (1998)
10.1002/PROS.20001
Vitamin D receptor gene polymorphisms and prostate cancer risk
M. K. Cheteri (2004)
10.1210/JC.2003-031979
Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization.
N. Binkley (2004)
10.1023/A:1008875819232
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
A. Nomura (2004)
10.1002/JBMR.5650111204
The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal mexican‐American women
C. Gross (1996)
10.1016/S0090-4295(99)80221-0
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
G. Schwartz (1995)
10.1002/EM.20000
Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer
D. Bodiwala (2004)
1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.
G. Schwartz (1997)
10.1016/S0303-7207(01)00406-3
Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene
G. Whitfield (2001)
10.1093/CLINCHEM/42.4.586
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer.
B. Hollis (1996)
10.1016/J.GENE.2004.05.014
Genetics and biology of vitamin D receptor polymorphisms.
A. Uitterlinden (2004)
10.1002/jcb.10345
Role of the vitamin D‐endocrine system in the pathophysiology of postmenopausal osteoporosis
B. Riggs (2003)
10.1111/j.1525-139X.2005.18403.x
VITAMIN D IN HEALTH AND DISEASE: Vitamin D and the Epidemiology of Prostate Cancer
G. Schwartz (2005)
10.1007/s004399900119
Vitamin D receptor polymorphisms as markers in prostate cancer
L. Correa-Cerro (1999)
The prevalence of hypovitaminosis D among US adults: data from the NHANES III.
Ashraf Zadshir (2005)
10.1046/j.1365-2265.2000.00909.x
Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25‐dihydroxyvitamin D3
E. Colin (2000)
Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
B. Lokeshwar (1999)
A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection.
T. Saijo (1991)
10.1210/MEND.14.3.0435
The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB.
P. Jurutka (2000)
10.1093/CARCIN/22.9.1343
Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes.
C. Luscombe (2001)
10.1038/367284A0
Prediction of bone density from vitamin D receptor alleles
N. Morrison (1994)
10.1001/ARCHINTE.1987.00370020179060
Diagnosis, staging, and surgical treatment of prostatic carcinoma.
W. J. Catalona (1987)
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
D. Peehl (1994)
10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
C. L. Hanchette (1992)
alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
G G Schwartz (1997)
10.1046/J.1525-1373.1999.D01-60.X
Vitamin D and prostate cancer.
S. Blutt (1999)
10.1359/jbmr.1998.13.11.1691
The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants
C. Gross (1998)



This paper is referenced by
10.1016/j.endonu.2011.07.007
Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer.
M. Varsavsky (2011)
10.1007/978-3-642-38983-2_16
Prevention of Prostate Cancer
A. Algotar (2014)
10.1155/2013/483687
Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment?
K. Crew (2013)
La Vitamina D y su Importancia en la Salud Humana
David Awad (2013)
10.1007/s40520-015-0447-8
Replication study of the vitamin D receptor (VDR) genotype association with skeletal muscle traits and sarcopenia
S. Walsh (2015)
10.1002/pros.23018
Risk of prostate cancer in African‐American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status
Channing J Paller (2015)
Association of vitamin D receptor with longevity and healthy aging.
F. Najmi Varzaneh (2013)
Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.
J. Li (2013)
10.1016/j.neulet.2016.06.041
Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: Revisited
S. Kang (2016)
10.1007/s00432-014-1706-3
Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis
Yong-hua Xu (2014)
Vitamin D and calcium: a systematic review of health outcomes.
M. Chung (2009)
The US Health Care System and Lagging Life Expectancy: A Case Study
S. Preston (2009)
Vitamin D: an old prohormone with an emergent role in chronic kidney disease.
G. Coen (2008)
Vitamin D status : determinants, optimal levels, and supplementation
C. Bacon (2009)
10.1159/000458427
1α,25(OH) 2D3 Sensitive Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Ishikawa Cells
N. Zeng (2017)
10.1007/s13277-013-1544-y
Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk
Yeqiong Xu (2013)
Randomized , double-blind , placebo-controlled trial of vitamin D supplementation in Parkinson disease 1 – 4
M. Suzuki (2013)
10.1371/journal.pone.0229638
Low serum 25-hydroxyvitamin D status in the pathogenesis of stress fractures in military personnel: An evidenced link to support injury risk management
R. Armstrong (2020)
10.1093/nar/gkq742
Natural and engineered nicking endonucleases—from cleavage mechanism to engineering of strand-specificity
S. Chan (2011)
10.3389/fimmu.2016.00053
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans
Ken Batai (2016)
10.1007/978-1-4939-0437-2_5
Vitamin D receptor polymorphisms and cancer.
S. Gandini (2014)
10.1111/J.1753-4887.2007.TB00345.X
Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk.
E. Giovannucci (2007)
10.1212/WNL.0b013e3181c7197b
25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men
Y. Slinin (2010)
10.1007/s00408-014-9648-8
Association of Vitamin D Receptor Gene Polymorphisms with Asthma Risk: Systematic Review and Updated Meta-analysis of Case–Control Studies
K. Tizaoui (2014)
10.1158/1055-9965.EPI-09-0544
Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review
L. Chen (2009)
10.1016/j.jns.2018.05.025
Vitamin D receptor (VDR) gene polymorphism and vascular dementia due to cerebral small vessel disease in an Asian Indian cohort
M. Supriya (2018)
10.4161/derm.1.1.7388
How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer? An examination using Hill’s criteria for causality
W. Grant (2009)
10.1016/j.gene.2015.02.024
Regulation of the vitamin D receptor gene by environment, genetics and epigenetics.
D. Saccone (2015)
10.1684/BDC.2013.1739
Pharmaco-prévention et nutri-prévention des cancers de la prostate
F. Eisinger (2013)
10.1158/1078-0432.CCR-17-2943
Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Y. Huang (2018)
10.1200/JCO.2009.27.9406
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.
S. Chang (2010)
10.18632/oncotarget.12837
Association of vitamin D receptor Fok I polymorphism with the risk of prostate cancer: a meta-analysis
Shaosan Kang (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar